25 XP   0   0   10

OliX PharmaceuticalsInc
Buy, Hold or Sell?

Let's analyse OliX PharmaceuticalsInc together

PenkeI guess you are interested in OliX PharmaceuticalsInc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of OliX PharmaceuticalsInc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about OliX PharmaceuticalsInc

I send you an email if I find something interesting about OliX PharmaceuticalsInc.

Quick analysis of OliX PharmaceuticalsInc (30 sec.)










What can you expect buying and holding a share of OliX PharmaceuticalsInc? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩3,144.08
Expected worth in 1 year
₩1,478.51
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
₩-1,665.57
Return On Investment
-10.9%

For what price can you sell your share?

Current Price per Share
₩15,220.00
Expected price per share
₩13,000 - ₩25,950
How sure are you?
50%

1. Valuation of OliX PharmaceuticalsInc (5 min.)




Live pricePrice per Share (EOD)

₩15,220.00

Intrinsic Value Per Share

₩-90,201.42 - ₩-107,098.68

Total Value Per Share

₩-87,057.34 - ₩-103,954.60

2. Growth of OliX PharmaceuticalsInc (5 min.)




Is OliX PharmaceuticalsInc growing?

Current yearPrevious yearGrowGrow %
How rich?$35.2m$34.1m-$1m-3.0%

How much money is OliX PharmaceuticalsInc making?

Current yearPrevious yearGrowGrow %
Making money-$3.3m-$3.4m$68.8k2.1%
Net Profit Margin-244.8%-80.5%--

How much money comes from the company's main activities?

3. Financial Health of OliX PharmaceuticalsInc (5 min.)




What can you expect buying and holding a share of OliX PharmaceuticalsInc? (5 min.)

Welcome investor! OliX PharmaceuticalsInc's management wants to use your money to grow the business. In return you get a share of OliX PharmaceuticalsInc.

What can you expect buying and holding a share of OliX PharmaceuticalsInc?

First you should know what it really means to hold a share of OliX PharmaceuticalsInc. And how you can make/lose money.

Speculation

The Price per Share of OliX PharmaceuticalsInc is ₩15,220. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of OliX PharmaceuticalsInc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in OliX PharmaceuticalsInc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩3,144.08. Based on the TTM, the Book Value Change Per Share is ₩-416.39 per quarter. Based on the YOY, the Book Value Change Per Share is ₩864.51 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of OliX PharmaceuticalsInc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.140.0%-0.240.0%-0.250.0%-0.380.0%-0.380.0%
Usd Book Value Change Per Share0.400.0%-0.290.0%0.610.0%0.110.0%0.110.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.400.0%-0.290.0%0.610.0%0.110.0%0.110.0%
Usd Price Per Share10.21-12.26-15.50-18.23-18.23-
Price to Earnings Ratio18.27--2.60--3.51--8.44--8.44-
Price-to-Total Gains Ratio25.76--13.43--12.42--33.20--33.20-
Price to Book Ratio4.64-5.48-12.59-9.22-9.22-
Price-to-Total Gains Ratio25.76--13.43--12.42--33.20--33.20-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share10.654
Number of shares93
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.290.11
Usd Total Gains Per Share-0.290.11
Gains per Quarter (93 shares)-27.1110.23
Gains per Year (93 shares)-108.4340.94
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-108-11804131
20-217-22608272
30-325-3340123113
40-434-4420164154
50-542-5500205195
60-651-6580246236
70-759-7660287277
80-867-8740327318
90-976-9820368359
100-1084-10900409400

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%2.018.00.010.0%2.018.00.010.0%2.018.00.010.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%5.015.00.025.0%5.015.00.025.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.020.00.0%0.00.020.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%5.015.00.025.0%5.015.00.025.0%5.015.00.025.0%

Fundamentals of OliX PharmaceuticalsInc

About OliX PharmaceuticalsInc

OliX Pharmaceuticals, Inc. focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX201A for idiopathic pulmonary fibrosis; OLX301 for age-related macular degeneration; and OLX301D for subretinal fibrosis. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.

Fundamental data was last updated by Penke on 2024-04-16 06:15:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of OliX PharmaceuticalsInc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit OliX PharmaceuticalsInc earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare OliX PharmaceuticalsInc to the  industry mean.
  • A Net Profit Margin of 30.4% means that ₩0.30 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of OliX PharmaceuticalsInc:

  • The MRQ is 30.4%. The company is making a huge profit. +2
  • The TTM is -244.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ30.4%TTM-244.8%+275.2%
TTM-244.8%YOY-80.5%-164.3%
TTM-244.8%5Y-818.2%+573.4%
5Y-818.2%10Y-818.2%0.0%
1.1.2. Return on Assets

Shows how efficient OliX PharmaceuticalsInc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare OliX PharmaceuticalsInc to the  industry mean.
  • 3.1% Return on Assets means that OliX PharmaceuticalsInc generated ₩0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of OliX PharmaceuticalsInc:

  • The MRQ is 3.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is -4.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ3.1%TTM-4.2%+7.3%
TTM-4.2%YOY-4.9%+0.7%
TTM-4.2%5Y-7.3%+3.2%
5Y-7.3%10Y-7.3%0.0%
1.1.3. Return on Equity

Shows how efficient OliX PharmaceuticalsInc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare OliX PharmaceuticalsInc to the  industry mean.
  • 6.4% Return on Equity means OliX PharmaceuticalsInc generated ₩0.06 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of OliX PharmaceuticalsInc:

  • The MRQ is 6.4%. Using its investors money, the company is less efficient in making profit.
  • The TTM is -10.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ6.4%TTM-10.5%+16.9%
TTM-10.5%YOY-26.9%+16.4%
TTM-10.5%5Y-17.2%+6.7%
5Y-17.2%10Y-17.2%0.0%

1.2. Operating Efficiency of OliX PharmaceuticalsInc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient OliX PharmaceuticalsInc is operating .

  • Measures how much profit OliX PharmaceuticalsInc makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare OliX PharmaceuticalsInc to the  industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of OliX PharmaceuticalsInc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-125.3%+125.3%
TTM-5Y-566.7%+566.7%
5Y-566.7%10Y-566.7%0.0%
1.2.2. Operating Ratio

Measures how efficient OliX PharmaceuticalsInc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 0.78 means that the operating costs are ₩0.78 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of OliX PharmaceuticalsInc:

  • The MRQ is 0.784. The company is efficient in keeping operating costs low. +1
  • The TTM is 3.269. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.784TTM3.269-2.485
TTM3.269YOY1.340+1.928
TTM3.2695Y4.152-0.883
5Y4.15210Y4.1520.000

1.3. Liquidity of OliX PharmaceuticalsInc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if OliX PharmaceuticalsInc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 4.90 means the company has ₩4.90 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of OliX PharmaceuticalsInc:

  • The MRQ is 4.897. The company is very able to pay all its short-term debts. +2
  • The TTM is 2.104. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ4.897TTM2.104+2.794
TTM2.104YOY1.706+0.398
TTM2.1045Y8.103-6.000
5Y8.10310Y8.1030.000
1.3.2. Quick Ratio

Measures if OliX PharmaceuticalsInc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare OliX PharmaceuticalsInc to the  industry mean.
  • A Quick Ratio of 2.67 means the company can pay off ₩2.67 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of OliX PharmaceuticalsInc:

  • The MRQ is 2.666. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.912. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.666TTM1.912+0.754
TTM1.912YOY2.678-0.766
TTM1.9125Y10.203-8.291
5Y10.20310Y10.2030.000

1.4. Solvency of OliX PharmaceuticalsInc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of OliX PharmaceuticalsInc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare OliX PharmaceuticalsInc to industry mean.
  • A Debt to Asset Ratio of 0.51 means that OliX PharmaceuticalsInc assets are financed with 51.0% credit (debt) and the remaining percentage (100% - 51.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of OliX PharmaceuticalsInc:

  • The MRQ is 0.510. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.567. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.510TTM0.567-0.057
TTM0.567YOY0.611-0.044
TTM0.5675Y0.404+0.163
5Y0.40410Y0.4040.000
1.4.2. Debt to Equity Ratio

Measures if OliX PharmaceuticalsInc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare OliX PharmaceuticalsInc to the  industry mean.
  • A Debt to Equity ratio of 105.3% means that company has ₩1.05 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of OliX PharmaceuticalsInc:

  • The MRQ is 1.053. The company is able to pay all its debts with equity. +1
  • The TTM is 1.335. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.053TTM1.335-0.283
TTM1.335YOY2.541-1.206
TTM1.3355Y1.212+0.123
5Y1.21210Y1.2120.000

2. Market Valuation of OliX PharmaceuticalsInc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings OliX PharmaceuticalsInc generates.

  • Above 15 is considered overpriced but always compare OliX PharmaceuticalsInc to the  industry mean.
  • A PE ratio of 18.27 means the investor is paying ₩18.27 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of OliX PharmaceuticalsInc:

  • The EOD is 19.067. Based on the earnings, the company is fair priced.
  • The MRQ is 18.266. Based on the earnings, the company is fair priced.
  • The TTM is -2.601. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD19.067MRQ18.266+0.802
MRQ18.266TTM-2.601+20.867
TTM-2.601YOY-3.511+0.909
TTM-2.6015Y-8.435+5.834
5Y-8.43510Y-8.4350.000
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of OliX PharmaceuticalsInc:

  • The EOD is -14.082. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -13.490. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.213. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-14.082MRQ-13.490-0.592
MRQ-13.490TTM-9.213-4.277
TTM-9.213YOY-9.351+0.138
TTM-9.2135Y-8.481-0.732
5Y-8.48110Y-8.4810.000
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of OliX PharmaceuticalsInc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of 4.64 means the investor is paying ₩4.64 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of OliX PharmaceuticalsInc:

  • The EOD is 4.841. Based on the equity, the company is fair priced.
  • The MRQ is 4.637. Based on the equity, the company is fair priced.
  • The TTM is 5.481. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.841MRQ4.637+0.204
MRQ4.637TTM5.481-0.844
TTM5.481YOY12.588-7.107
TTM5.4815Y9.223-3.741
5Y9.22310Y9.2230.000
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of OliX PharmaceuticalsInc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--566.031-416.392+174%864.514-35%157.204+260%157.204+260%
Book Value Per Share--3144.0803212.072-2%3562.068-12%4541.949-31%4541.949-31%
Current Ratio--4.8972.104+133%1.706+187%8.103-40%8.103-40%
Debt To Asset Ratio--0.5100.567-10%0.611-16%0.404+26%0.404+26%
Debt To Equity Ratio--1.0531.335-21%2.541-59%1.212-13%1.212-13%
Dividend Per Share----0%-0%-0%-0%
Eps--199.555-343.224+272%-355.673+278%-540.283+371%-540.283+371%
Free Cash Flow Per Share---270.199-520.436+93%-602.314+123%-690.611+156%-690.611+156%
Free Cash Flow To Equity Per Share---270.199-523.262+94%1446.852-119%189.310-243%189.310-243%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---107098.679--------
Intrinsic Value_10Y_min---90201.419--------
Intrinsic Value_1Y_max---4645.190--------
Intrinsic Value_1Y_min---4559.125--------
Intrinsic Value_3Y_max---18595.804--------
Intrinsic Value_3Y_min---17659.441--------
Intrinsic Value_5Y_max---38139.217--------
Intrinsic Value_5Y_min---35000.573--------
Market Cap99020102400.000-136%233422286220.000257910540942.500-9%303353704500.000-23%274808917238.500-15%274808917238.500-15%
Net Profit Margin--0.304-2.448+905%-0.805+365%-8.182+2791%-8.182+2791%
Operating Margin----0%-1.2530%-5.6670%-5.6670%
Operating Ratio--0.7843.269-76%1.340-42%4.152-81%4.152-81%
Pb Ratio4.841+4%4.6375.481-15%12.588-63%9.223-50%9.223-50%
Pe Ratio19.067+4%18.266-2.601+114%-3.511+119%-8.435+146%-8.435+146%
Price Per Share15220.000+4%14580.00017510.000-17%22137.500-34%26042.000-44%26042.000-44%
Price To Free Cash Flow Ratio-14.082-4%-13.490-9.213-32%-9.351-31%-8.481-37%-8.481-37%
Price To Total Gains Ratio26.889+4%25.758-13.432+152%-12.415+148%-33.201+229%-33.201+229%
Quick Ratio--2.6661.912+39%2.6780%10.203-74%10.203-74%
Return On Assets--0.031-0.042+235%-0.049+258%-0.073+336%-0.073+336%
Return On Equity--0.064-0.105+264%-0.269+520%-0.172+368%-0.172+368%
Total Gains Per Share--566.031-416.392+174%864.514-35%157.204+260%157.204+260%
Usd Book Value--35235168.59133159301.490+6%34168115.417+3%29426781.470+20%29426781.470+20%
Usd Book Value Change Per Share--0.396-0.291+174%0.605-35%0.110+260%0.110+260%
Usd Book Value Per Share--2.2012.248-2%2.493-12%3.179-31%3.179-31%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.140-0.240+272%-0.249+278%-0.378+371%-0.378+371%
Usd Free Cash Flow---3028075.330-5291413.775+75%-5777521.976+91%-5743317.930+90%-5743317.930+90%
Usd Free Cash Flow Per Share---0.189-0.364+93%-0.422+123%-0.483+156%-0.483+156%
Usd Free Cash Flow To Equity Per Share---0.189-0.366+94%1.013-119%0.133-243%0.133-243%
Usd Market Cap69314071.680-136%163395600.354180537378.660-9%212347593.150-23%192366242.067-15%192366242.067-15%
Usd Price Per Share10.654+4%10.20612.257-17%15.496-34%18.229-44%18.229-44%
Usd Profit--2236382.512-3342796.821+249%-3411686.668+253%-3571715.356+260%-3571715.356+260%
Usd Revenue--7354191.2852986248.202+146%1631056.639+351%1178224.425+524%1178224.425+524%
Usd Total Gains Per Share--0.396-0.291+174%0.605-35%0.110+260%0.110+260%
 EOD+3 -5MRQTTM+26 -6YOY+19 -135Y+21 -1110Y+21 -11

3.2. Fundamental Score

Let's check the fundamental score of OliX PharmaceuticalsInc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1519.067
Price to Book Ratio (EOD)Between0-14.841
Net Profit Margin (MRQ)Greater than00.304
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.666
Current Ratio (MRQ)Greater than14.897
Debt to Asset Ratio (MRQ)Less than10.510
Debt to Equity Ratio (MRQ)Less than11.053
Return on Equity (MRQ)Greater than0.150.064
Return on Assets (MRQ)Greater than0.050.031
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of OliX PharmaceuticalsInc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.746
Ma 20Greater thanMa 5015,111.500
Ma 50Greater thanMa 10015,806.200
Ma 100Greater thanMa 20015,115.200
OpenGreater thanClose15,440.000
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Income before Tax  -3,003,017-4,467,679-7,470,696-1,015,793-8,486,4893,560,086-4,926,4037,640,3662,713,963
Operating Income  -3,021,103-4,795,093-7,816,195220,699-7,595,4962,551,807-5,043,6897,313,7262,270,038
Net Income from Continuing Operations  -2,008,114-6,495,564-8,503,678-362,769-8,866,4473,940,044-4,926,4038,121,2353,194,832



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets102,825,050
Total Liabilities52,489,095
Total Stockholder Equity49,854,508
 As reported
Total Liabilities 52,489,095
Total Stockholder Equity+ 49,854,508
Total Assets = 102,825,050

Assets

Total Assets102,825,050
Total Current Assets32,141,698
Long-term Assets70,683,352
Total Current Assets
Cash And Cash Equivalents 11,982,762
Short-term Investments 13,941,856
Net Receivables 3,558,171
Inventory 468,409
Total Current Assets  (as reported)32,141,698
Total Current Assets  (calculated)29,951,199
+/- 2,190,499
Long-term Assets
Property Plant Equipment 43,909,712
Intangible Assets 1,980,624
Long-term Assets  (as reported)70,683,352
Long-term Assets  (calculated)45,890,336
+/- 24,793,016

Liabilities & Shareholders' Equity

Total Current Liabilities6,563,264
Long-term Liabilities45,925,831
Total Stockholder Equity49,854,508
Total Current Liabilities
Other Current Liabilities 0
Total Current Liabilities  (as reported)6,563,264
Total Current Liabilities  (calculated)0
+/- 6,563,264
Long-term Liabilities
Long term Debt 35,361,637
Capital Lease Obligations Min Short Term Debt3,995,709
Long-term Liabilities Other 0
Long-term Liabilities  (as reported)45,925,831
Long-term Liabilities  (calculated)39,357,346
+/- 6,568,485
Total Stockholder Equity
Total Stockholder Equity (as reported)49,854,508
Total Stockholder Equity (calculated)0
+/- 49,854,508
Other
Capital Stock8,446,735
Common Stock Shares Outstanding 16,010
Net Debt 23,378,875
Net Invested Capital 84,779,290
Net Working Capital 25,578,434
Property Plant and Equipment Gross 50,157,512



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
56,060,571
53,604,041
49,772,712
45,207,279
41,235,184
37,274,461
33,931,551
78,577,366
75,112,266
74,019,833
66,771,865
86,671,974
79,303,768
130,174,486
125,836,384
132,651,480
124,444,442
108,406,171
101,886,168
102,825,050
102,825,050101,886,168108,406,171124,444,442132,651,480125,836,384130,174,48679,303,76886,671,97466,771,86574,019,83375,112,26678,577,36633,931,55137,274,46141,235,18445,207,27949,772,71253,604,04156,060,571
   > Total Current Assets 
49,057,542
46,577,217
42,321,453
37,439,676
33,538,085
29,106,697
25,995,870
69,046,816
64,984,953
63,925,224
56,617,428
52,239,572
44,608,162
90,722,968
84,856,928
65,045,504
59,317,910
46,179,699
34,968,662
32,141,698
32,141,69834,968,66246,179,69959,317,91065,045,50484,856,92890,722,96844,608,16252,239,57256,617,42863,925,22464,984,95369,046,81625,995,87029,106,69733,538,08537,439,67642,321,45346,577,21749,057,542
       Cash And Cash Equivalents 
5,361,972
2,985,045
10,972,956
4,954,473
6,413,671
1,850,512
1,680,241
11,328,809
7,270,553
17,067,283
15,212,083
34,336,736
0
0
0
4,930,268
8,046,626
9
7,028,999
11,982,762
11,982,7627,028,99998,046,6264,930,26800034,336,73615,212,08317,067,2837,270,55311,328,8091,680,2411,850,5126,413,6714,954,47310,972,9562,985,0455,361,972
       Short-term Investments 
24,000,000
24,000,000
19,000,000
15,000,000
0
0
22,412,591
56,781,876
56,703,383
45,856,359
40,403,200
15,420,680
23,396,120
24,295,191
66,103,449
56,941,476
44,786,673
35,627,209
24,344,716
13,941,856
13,941,85624,344,71635,627,20944,786,67356,941,47666,103,44924,295,19123,396,12015,420,68040,403,20045,856,35956,703,38356,781,87622,412,5910015,000,00019,000,00024,000,00024,000,000
       Net Receivables 
389,075
539,226
57,358
409,854
378,968
513,632
437,027
446,565
610,581
156,141
307,020
92,481
154,327
703,651
634,667
1,050,113
759,351
1,282,258
256,820
3,558,171
3,558,171256,8201,282,258759,3511,050,113634,667703,651154,32792,481307,020156,141610,581446,565437,027513,632378,968409,85457,358539,226389,075
       Inventory 
548,290
442,508
401,059
365,823
213,407
206,886
206,886
304,171
306,836
337,120
184,185
374,129
382,114
408,023
452,805
657,172
676,100
680,767
697,361
468,409
468,409697,361680,767676,100657,172452,805408,023382,114374,129184,185337,120306,836304,171206,886206,886213,407365,823401,059442,508548,290
       Other Current Assets 
801,345
986,661
1,208,755
1,100,812
1,385,369
1,471,489
1,255,665
178,263
78,796
0
0
0
0
130,281
358,865
99,004
0
0
-1
0
0-10099,004358,865130,281000078,796178,2631,255,6651,471,4891,385,3691,100,8121,208,755986,661801,345
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
67,605,976
65,126,532
62,226,472
66,917,506
70,683,352
70,683,35266,917,50662,226,47265,126,53267,605,976000000000000000
       Property Plant Equipment 
5,267,913
5,227,993
5,511,506
5,911,249
5,849,201
6,260,449
6,072,259
6,180,366
6,657,044
6,608,801
6,849,033
31,525,481
31,755,105
32,457,600
34,796,801
37,232,153
38,832,561
41,228,861
42,159,867
43,909,712
43,909,71242,159,86741,228,86138,832,56137,232,15334,796,80132,457,60031,755,10531,525,4816,849,0336,608,8016,657,0446,180,3666,072,2596,260,4495,849,2015,911,2495,511,5065,227,9935,267,913
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000
       Intangible Assets 
1,344,147
1,377,194
1,394,593
1,410,663
1,613,753
1,636,280
1,592,512
2,529,200
2,519,555
2,520,668
2,552,871
2,134,371
2,128,060
2,108,382
2,185,537
2,107,428
2,055,671
2,040,163
1,995,037
1,980,624
1,980,6241,995,0372,040,1632,055,6712,107,4282,185,5372,108,3822,128,0602,134,3712,552,8712,520,6682,519,5552,529,2001,592,5121,636,2801,613,7531,410,6631,394,5931,377,1941,344,147
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
00100000000000000000
> Total Liabilities 
3,189,098
3,739,376
3,037,592
3,408,995
2,640,106
2,866,856
3,397,572
33,291,823
36,925,491
40,133,857
41,420,388
68,150,860
69,200,099
67,477,735
69,297,822
66,744,088
68,758,848
66,219,940
60,612,227
52,489,095
52,489,09560,612,22766,219,94068,758,84866,744,08869,297,82267,477,73569,200,09968,150,86041,420,38840,133,85736,925,49133,291,8233,397,5722,866,8562,640,1063,408,9953,037,5923,739,3763,189,098
   > Total Current Liabilities 
2,894,567
3,478,268
2,688,063
2,754,476
2,058,199
1,998,424
2,182,075
4,488,211
4,884,904
8,347,014
8,397,614
40,365,162
42,508,735
41,938,255
43,168,862
39,543,152
42,132,109
40,205,464
36,384,678
6,563,264
6,563,26436,384,67840,205,46442,132,10939,543,15243,168,86241,938,25542,508,73540,365,1628,397,6148,347,0144,884,9044,488,2112,182,0751,998,4242,058,1992,754,4762,688,0633,478,2682,894,567
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,230,313
19,998,641
20,806,721
19,830,395
0
019,830,39520,806,72119,998,64119,230,313000000000000000
       Accounts payable 
385,230
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000385,230
       Other Current Liabilities 
2,487,269
3,436,336
2,639,145
2,713,889
2,013,631
1,962,693
2,008,357
4,149,544
4,472,510
0
0
0
0
9,552,054
24,165,750
19,014,350
1
1
-1
0
0-11119,014,35024,165,7509,552,05400004,472,5104,149,5442,008,3571,962,6932,013,6312,713,8892,639,1453,436,3362,487,269
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,905,774
26,287,802
25,627,750
24,227,549
45,925,831
45,925,83124,227,54925,627,75026,287,80226,905,774000000000000000
       Long term Debt Total 
0
0
50,785
206,935
217,395
469,499
304,178
14,268,045
14,957,525
15,822,337
16,379,335
20,377,705
20,384,555
20,397,738
22,452,994
23,825,820
23,918,619
24,001,503
0
0
0024,001,50323,918,61923,825,82022,452,99420,397,73820,384,55520,377,70516,379,33515,822,33714,957,52514,268,045304,178469,499217,395206,93550,78500
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,765,689
4,642,216
4,655,877
4,489,021
3,995,709
3,995,7094,489,0214,655,8774,642,2164,765,689000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000
> Total Stockholder Equity
52,871,473
49,864,664
46,735,119
41,798,285
38,595,079
34,407,605
30,533,979
45,285,543
38,186,774
33,885,976
25,351,477
18,521,114
10,103,669
62,696,751
56,538,562
65,907,392
55,685,595
42,186,232
40,838,546
49,854,508
49,854,50840,838,54642,186,23255,685,59565,907,39256,538,56262,696,75110,103,66918,521,11425,351,47733,885,97638,186,77445,285,54330,533,97934,407,60538,595,07941,798,28546,735,11949,864,66452,871,473
   Common Stock
3,252,961
3,252,961
3,253,561
3,265,061
3,265,461
3,281,461
3,284,461
6,771,030
6,851,580
6,851,580
6,851,580
6,851,580
6,851,580
6,851,580
6,851,580
6,851,580
6,867,080
6,867,080
0
0
006,867,0806,867,0806,851,5806,851,5806,851,5806,851,5806,851,5806,851,5806,851,5806,851,5806,771,0303,284,4613,281,4613,265,4613,265,0613,253,5613,252,9613,252,961
   Retained Earnings Total Equity00000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000
   Capital Surplus 
0
0
72,767,954
73,217,233
71,549,831
73,266,357
73,601,811
92,921,712
93,917,203
92,909,087
92,908,201
92,908,201
92,908,201
151,894,504
151,894,504
151,894,504
152,385,135
152,384,530
0
0
00152,384,530152,385,135151,894,504151,894,504151,894,50492,908,20192,908,20192,908,20192,909,08793,917,20392,921,71273,601,81173,266,35771,549,83173,217,23372,767,95400
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
1,043,889
1,403,268
169,385
1,792,312
1,481,947
1,353,940
1,585,745
1,764,623
1,523,659
-541,258
-435,828
-646,440
-568,767
4,348,360
4,758,923
8,885,456
1,652,105
-3,479,346
0
0
00-3,479,3461,652,1058,885,4564,758,9234,348,360-568,767-646,440-435,828-541,2581,523,6591,764,6231,585,7451,353,9401,481,9471,792,312169,3851,403,2681,043,889



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue17,064,275
Cost of Revenue-0
Gross Profit17,064,27517,064,275
 
Operating Income (+$)
Gross Profit17,064,275
Operating Expense-35,249,618
Operating Income-18,185,343-18,185,343
 
Operating Expense (+$)
Research Development18,478,378
Selling General Administrative3,692,842
Selling And Marketing Expenses0
Operating Expense35,249,61822,171,220
 
Net Interest Income (+$)
Interest Income1,267,621
Interest Expense-3,491,742
Other Finance Cost-421,583
Net Interest Income-1,802,538
 
Pretax Income (+$)
Operating Income-18,185,343
Net Interest Income-1,802,538
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-18,169,624-18,185,343
EBIT - interestExpense = -3,491,742
-19,101,696
-15,609,954
Interest Expense3,491,742
Earnings Before Interest and Taxes (EBIT)0-14,677,882
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-18,169,624
Tax Provision-932,072
Net Income From Continuing Ops-19,101,696-19,101,696
Net Income-19,101,696
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net01,802,538
 

Technical Analysis of OliX PharmaceuticalsInc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of OliX PharmaceuticalsInc. The general trend of OliX PharmaceuticalsInc is BEARISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine OliX PharmaceuticalsInc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-14.3%) Bearish trend (14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of OliX PharmaceuticalsInc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 17,820 < 18,490 < 25,950.

The bearish price targets are: 13,870 > 13,170 > 13,000.

Tweet this
OliX PharmaceuticalsInc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of OliX PharmaceuticalsInc. The current mas is .

The long score for the Moving Averages is 6/14.
The longshort score for the Moving Averages is -2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

OliX PharmaceuticalsInc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of OliX PharmaceuticalsInc. The current macd is -154.15162382.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the OliX PharmaceuticalsInc price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for OliX PharmaceuticalsInc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the OliX PharmaceuticalsInc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
OliX PharmaceuticalsInc Daily Moving Average Convergence/Divergence (MACD) ChartOliX PharmaceuticalsInc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of OliX PharmaceuticalsInc. The current adx is 17.13.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy OliX PharmaceuticalsInc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
OliX PharmaceuticalsInc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of OliX PharmaceuticalsInc. The current sar is 14,197.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
OliX PharmaceuticalsInc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of OliX PharmaceuticalsInc. The current rsi is 48.75. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
OliX PharmaceuticalsInc Daily Relative Strength Index (RSI) ChartOliX PharmaceuticalsInc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of OliX PharmaceuticalsInc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the OliX PharmaceuticalsInc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
OliX PharmaceuticalsInc Daily Stochastic Oscillator ChartOliX PharmaceuticalsInc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of OliX PharmaceuticalsInc. The current cci is 37.25.

OliX PharmaceuticalsInc Daily Commodity Channel Index (CCI) ChartOliX PharmaceuticalsInc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of OliX PharmaceuticalsInc. The current cmo is -0.31880511.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
OliX PharmaceuticalsInc Daily Chande Momentum Oscillator (CMO) ChartOliX PharmaceuticalsInc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of OliX PharmaceuticalsInc. The current willr is -47.87644788.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that OliX PharmaceuticalsInc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
OliX PharmaceuticalsInc Daily Williams %R ChartOliX PharmaceuticalsInc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of OliX PharmaceuticalsInc.

OliX PharmaceuticalsInc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of OliX PharmaceuticalsInc. The current atr is 854.66.

OliX PharmaceuticalsInc Daily Average True Range (ATR) ChartOliX PharmaceuticalsInc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of OliX PharmaceuticalsInc. The current obv is 7,012,686.

OliX PharmaceuticalsInc Daily On-Balance Volume (OBV) ChartOliX PharmaceuticalsInc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of OliX PharmaceuticalsInc. The current mfi is 61.48.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
OliX PharmaceuticalsInc Daily Money Flow Index (MFI) ChartOliX PharmaceuticalsInc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for OliX PharmaceuticalsInc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-23ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-04MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

OliX PharmaceuticalsInc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of OliX PharmaceuticalsInc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5048.746
Ma 20Greater thanMa 5015,111.500
Ma 50Greater thanMa 10015,806.200
Ma 100Greater thanMa 20015,115.200
OpenGreater thanClose15,440.000
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of OliX PharmaceuticalsInc with someone you think should read this too:
  • Are you bullish or bearish on OliX PharmaceuticalsInc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about OliX PharmaceuticalsInc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about OliX PharmaceuticalsInc

I send you an email if I find something interesting about OliX PharmaceuticalsInc.


Comments

How you think about this?

Leave a comment

Stay informed about OliX PharmaceuticalsInc.

Receive notifications about OliX PharmaceuticalsInc in your mailbox!